# DESCRIPTION

## BACKGROUND

- motivate immune complex properties
- identify need for improved methods

## SUMMARY

- introduce complement mediated disorders
- describe formation of multivalent immune complexes
- motivate prevention of immune complex formation
- summarize strategies to minimize risk of toxicity
- introduce weaning off period
- describe apheresis procedure
- introduce use of antigen fragments
- specify applicable disorders (PNH or aHUS)
- list examples of first and second antibodies
- describe non-competitive antibodies
- introduce washout period
- specify bodily fluid (blood or ocular fluid)
- describe first antibody (eculizumab or ravulizumab)
- specify washout period for eculizumab
- specify washout period for ravulizumab
- describe removal of first antibody
- introduce use of peptide antigens
- describe non-competitive antibodies
- introduce measurement of multivalent immune complex
- describe method for treating patient
- contact biological sample with second antibody
- measure level of multivalent immune complexes
- determine if level exceeds threshold
- administer adjusted regimen of second antibody
- describe method for determining adjusted regimen
- contact biological sample with second antibody
- measure level of multivalent immune complexes
- determine if level exceeds threshold
- adjust regimen of second antibody
- describe method for switching patient to second antibody
- contact biological sample with second antibody
- measure level of multivalent immune complexes
- determine if level exceeds threshold
- administer adjusted regimen of second antibody
- wean patient from first antibody therapy
- describe additional techniques for clearing first antibody
- list examples of anti-C5 antibodies
- describe eculizumab
- describe ravulizumab
- define anti-C5 antibody
- specify embodiments of anti-C5 antibody
- describe binding properties of anti-C5 antibody
- specify threshold level for multivalent immune complexes
- describe determination of threshold level
- describe deferral of second anti-C5 antibody administration
- specify dosing regimens for anti-C5 antibody
- describe administration of first or second anti-C5 antibody
- specify embodiments for PNH treatment
- specify embodiments for aHUS treatment
- specify embodiments for MG treatment
- describe adjusted therapeutic regimen
- specify embodiments for PNH treatment with adjusted regimen
- specify embodiments for aHUS treatment with adjusted regimen
- specify embodiments for MG treatment with adjusted regimen
- describe administration of anti-C5 antibody to pediatric patients
- specify dosing regimens for pediatric patients
- describe administration of anti-C5 antibody to patients with PNH
- describe administration of anti-C5 antibody to patients with aHUS
- describe administration of anti-C5 antibody to patients with MG
- specify embodiments for anti-C5 antibody administration
- describe administration of SOLIRIS to patients
- specify dosing regimens for SOLIRIS
- describe administration of SOLIRIS to pediatric patients
- describe anti-C5 antibody
- specify CDR sequences
- specify heavy chain variable region
- specify light chain variable region
- specify heavy chain polypeptide
- specify light chain polypeptide
- specify heavy chain constant region
- administer SOLIRIS to pediatric patient
- specify dose regimen for pediatric patient
- administer SOLIRIS to adult patient
- specify dose regimen for adult patient
- describe ULTOMIRIS
- specify CDR sequences
- specify heavy chain variable region
- specify light chain variable region
- specify heavy chain polypeptide
- specify light chain polypeptide
- specify heavy chain constant region
- administer ULTOMIRIS to pediatric patient
- specify dose regimen for pediatric patient
- administer ULTOMIRIS to adult patient
- specify dose regimen for adult patient
- describe administration methods
- specify biological samples
- contact biological sample with anti-C5 antibody
- specify complement mediated disorders
- describe treatment methods
- assess treatment efficacy
- describe use of second anti-C5 antibody
- specify non-competitive second anti-C5 antibody
- specify washout period
- prevent multivalent immune complex formation
- specify first anti-C5 antibody
- specify second anti-C5 antibody
- specify biosimilar antibodies
- specify preferred second antibodies

## DETAILED DESCRIPTION

### I. General Definitions

- define "and/or"
- define "about"
- define range of values
- define "plurality"
- define "first" and "second"
- define "substantially"
- define "marker"
- define "panel"
- define "modulate"
- define "enhance" or "increase"
- define "inhibit" or "reduce"
- define "reducing"
- define "likelihood"
- define "at risk"
- define "outcome"
- define "control"
- define "reference sample"
- define "test sample"
- define "threshold"
- define "level"
- define "subject" or "patient"
- define "pediatric" patient
- define "adult" patient
- define "in need of prevention"
- define "in need of treatment"
- define "treat" or "treating"
- define "prevent"
- define "symptom"
- define "sign"
- define "administration" or "administering"
- define "contact"
- define "transfusion"
- define "intravenous"
- define "effective treatment"
- define "effective amount"
- define "loading dose"
- define "maintenance" and "maintenance phase"
- define "therapeutic dose"
- define "sub-therapeutic"
- define "serum trough level"
- define "peak serum level"
- define "average serum level"
- define "inhibitor" or "antagonist"
- define "antibody"
- define "competitive" and "non-competitive" antibodies
- define "biosimilar"
- define "ka", "kd", and "KD"
- define "C5 inhibition"
- define "washout"

### II. Anti-C5 Antibodies

- define antibody
- describe types of antibodies
- introduce anti-C5 antibodies
- describe function of anti-C5 antibodies
- introduce ravulizumab
- describe structure of ravulizumab
- describe function of ravulizumab
- introduce BNJ421
- describe structure of BNJ421
- describe function of BNJ421
- define CDRs
- describe methods for defining CDRs
- introduce 7086 antibody
- describe structure of 7086 antibody
- describe function of 7086 antibody
- introduce 8110 antibody
- describe structure of 8110 antibody
- describe function of 8110 antibody
- introduce 305LO5 antibody
- describe structure of 305LO5 antibody
- describe function of 305LO5 antibody
- introduce SKY59 antibody
- describe structure of SKY59 antibody
- describe function of SKY59 antibody
- introduce pozelimab
- describe structure of pozelimab
- describe function of pozelimab
- introduce anti-C5 antibodies
- list known substitutions for enhancing binding affinity
- describe variant constant region with substitutions
- specify number of amino acid substitutions
- list specific substitutions and their positions
- describe shifted mutation locations due to antibody engineering
- specify additional substitution positions
- list specific substitutions at each position
- describe suitable anti-C5 antibodies
- specify binding affinity of anti-C5 antibodies
- describe methods for determining antibody binding
- define terms for antibody-antigen interaction
- describe measurement of affinity constants
- specify conditions for measuring kinetics of antibody binding
- describe blocking effect of anti-C5 antibody
- explain pro-inflammatory effects of C5a
- explain generation of C5b-9 membrane attack complex
- summarize inhibitory effect of anti-C5 antibody
- introduce anti-C5 antibodies
- motivate inhibition of C5 cleavage
- describe hemolytic assays
- describe ELISA
- describe C5a generation measurement
- describe C5b-9 neoepitope-specific antibodies
- describe classical complement pathway-mediated hemolysis
- describe alternative pathway-mediated hemolysis
- describe CH50 eq assay
- define inhibition of terminal complement activity
- describe substantial inhibition
- describe anti-C5 antibody with amino acid substitutions
- describe epitope mapping methods
- describe competition experiments
- describe binding to different domains in C5
- describe generation of anti-C5 antibodies
- describe immortalization of spleen cells
- describe screening for antibody production
- describe enhancement of antibody yield
- describe isolation of DNA sequences
- describe administration of anti-C5 antibodies
- describe intravenous administration
- describe subcutaneous administration

### III. Multivalent Immune Complexes

- define multivalent immune complex
- motivate prevention of multivalent immune complex formation
- describe contacting step for multivalent immune complex formation
- describe in vivo contacting step
- describe ex vivo or in vitro contacting step
- measure level of multivalent immune complexes
- determine level by size exclusion chromatography
- determine level by multi-angle light scattering
- determine threshold level of multivalent immune complexes

### IV. Complement Mediated Disorders

- introduce complement mediated disorders
- list exemplary complement mediated disorders
- specify aHUS as a complement mediated disorder
- specify PNH as a complement mediated disorder

### V. Therapeutic Regimens and Adjusted Regimens

- describe therapeutic regimens
- specify administration of anti-C5 antibodies
- introduce adjusted regimens
- describe modifications to dosing or scheduling
- specify sub-therapeutic dose
- describe moderated administration rate or interval
- describe moderated dose
- specify reduced dose and/or frequency
- describe embodiment of anti-C5 antibody
- describe administration of SOLIRIS to adult patient with PNH
- describe administration of SOLIRIS to adult patient with aHUS
- describe administration of SOLIRIS to adult patient with MG
- describe adjusted regimen for therapy of complement mediated disorder
- define therapeutic regimens
- specify first anti-C5 antibody
- specify administration dose
- specify patient weight ranges
- specify second anti-C5 antibody
- specify administration dose
- specify patient weight ranges
- specify third anti-C5 antibody
- specify administration dose
- specify patient weight ranges
- specify fourth anti-C5 antibody
- specify administration dose
- specify patient weight ranges
- specify fifth anti-C5 antibody
- specify administration dose
- specify patient weight ranges
- specify sixth anti-C5 antibody
- specify administration dose
- specify patient weight ranges
- specify seventh anti-C5 antibody
- specify administration dose
- specify patient weight ranges
- specify eighth anti-C5 antibody
- specify administration dose
- specify patient weight ranges
- specify ninth anti-C5 antibody
- specify administration dose
- specify patient weight ranges
- specify tenth anti-C5 antibody

### VI. Methods of Treatment

- outline treatment method
- describe weaning from first antibody

### VII. Methods of Determining Adjusted Regimens

- outline regimen determination method
- describe weaning from first antibody

### VIII. Methods for Switching a Patient from a First C5-Antibody to a Second C5-Antibody

- outline switching method
- describe measuring immune complexes
- describe administering adjusted regimen
- describe weaning from first antibody

### IX. Additional Treatments

- introduce additional techniques
- list exemplary techniques

## EXAMPLE

### Example 1

- introduce monoclonal antibody (mAb) development
- motivate consideration of immune complex properties
- state objective of the study
- describe size exclusion chromatography (SEC) method
- describe multi-angle light scattering (MALS) method
- describe bio-layer interferometry method
- describe hemolysis assessment method
- describe high performance liquid chromatography (HPLC) method
- describe sample preparation for SEC
- describe SEC results for crovalimab mimetic
- describe SEC results for pozelimab mimetic
- describe results for ravulizumab
- summarize results for crovalimab mimetic and pozelimab mimetic
- summarize results for ravulizumab
- discuss implications of multivalent complex formation
- highlight importance of understanding complex properties
- suggest monitoring and mitigation processes
- discuss potential proinflammatory effects of multivalent complexes
- conclude study findings

